Within the PD-(L)1 class, Keytruda is responsible for over 55% of the total global sales. Its current revenue total makes ...

Researchers conducted a nationwide cohort study using data from the Taiwan National Health Insurance database and the Taiwan ...

A new clinical study shows that an inhibitor of Fas ligand (FasL), also called CD95 ligand (CD95L), led to a faster recovery ...

As many as 40% of cancer patients receiving immune checkpoint inhibitors experience immune-related adverse events.

Reducing the risk of metastatic relapse in patients with resectable soft tissue sarcomas is crucial for improving outcomes, because metastasis is the primary cause of mortality in this population.

However, the landscape began to shift with the development of immune checkpoint inhibitors, which release “the brakes” on ...

The combination of THIO and Libtayo has shown promising results among patients with advanced checkpoint inhibitor-resistant ...

-- 27% relative risk reduction of progression or death with GRANITE vs. control in all treated population (HR=0.73 [90% CI, 0.44, 1.21]) -- -- 50% relative risk reduction of progression or death with ...

Beyond Cancer announced key data demonstrating the efficacy of Low Volume Ultra-High Concentration Nitric Oxide, LV UNO, when combined with ...

Fecal microbiota transplantation has significantly improved progression-free survival in patients with metastatic renal cell ...

By Ayako Wakatsuki Pedersen, Ph.D., Senior Vice President of Translational Research at IO Biotech | Making the tumor microenvironment hostile to cancer cells and immune-suppressive cells may transform ...